CALCIMEDICA INC CALC
ASignal's systematic analysis rates CALC as Bearish.
Reflects the latest available analysis · analyzed Nov 13, 2026
The case on CALC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current ratio of 4.96x indicates strong short-term liquidity
- Quick ratio of 4.80x suggests solid near-term financial stability
- Positive cash balance with $13.77M in total cash
- Price near lower Bollinger Band (1.26 vs 0.96), suggesting potential mean reversion
- Negative return on equity (-763.32%) indicates severe profitability issues
- Negative return on assets (-80.28%) reflects poor capital efficiency
- Debt-to-equity ratio of 1.63x is high, especially for a small-cap biotech
- Negative EV/EBITDA (-0.08x) and lack of profitability
- Price below both SMA20 (1.33) and SMA50 (1.54), indicating downtrend
- Negative price momentum (-0.10)
See the full verdict on CALC
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CALC
Most investors never get a second opinion, let alone several. ASignal runs CALC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.